Navigation Links
NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009
Date:9/10/2009

NEW YORK, Sept. 10 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. (Privately Held) today announced that Chief Executive Officer Dr. Allan E. Rubenstein will be presenting at two industry conferences during the month of September. The first presentation will take place on September 11th, 2009 at 11:40am as part of the Rodman & Renshaw 11th Annual Healthcare Conference in New York, New York. The second presentation will take place on September 23, 2009 at 4:15pm as part of the Life Sciences Summit 2009 in Hauppauge, New York. All times are local time.

Dr. Rubenstein will be presenting an overview of the Company's preclinical results related to its series of heat shock protein 90 (Hsp90) inhibitors, speak about the Company's forward drug development strategy and timeline, and present high-level fiscal results for 2009.

About NexGenix: NexGenix Pharmaceuticals Holdings, Inc. is a privately-held biotechnology company based in New York City. The Company's portfolio consists of a series of Hsp90 inhibitors, a novel target therapy for oncology and neurodegenerative disorders, which has attracted an enormous amount of development interest in the past several years. The Company's proprietary Hsp90 screening platform has already generated over 300 potential compounds. From this group, three lead drug candidates have been identified on the basis of superior efficacy, safety, and the ability to cross the blood brain barrier. The product profiles lend themselves to address diseases such as glioblastoma (or "glioma", commonly known as malignant brain tumor) and other cancers, as well as neurodegenerative disorders including the motor neuron disease ALS (Lou Gehrig's disease) and Parkinson's disease. Each of these indications represents a world-wide market of at least $1B/year. In addition, the Company has a clinical stage intralesional treatment for dermal neurofibromas, the most common lesion in Neurofibromatosis Type 1, and a research stage program in inhibitors of p21-activated kinase for indications including Neurofibromatosis Type 2, and Autism Spectrum Disorders.


'/>"/>
SOURCE NexGenix Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
2. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
3. ISTA Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
4. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
5. Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
6. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
7. Rib-X Pharmaceuticals to Present at the 49th ICAAC
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
9. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
10. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
11. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 AskLinkerReports.com has published a report ... Amyloglucosidase Industry 2016 Market Research Report. From a basic outline ... overview are all covered in the report. This report projects ... analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... Dec. 8, 2016  Renova™ Therapeutics, a biotechnology ... failure and type 2 diabetes, announced that it ... adeno-associated virus (AAV) vector developed in the laboratory ... at Stanford University. The company plans to use ... therapy product pipeline. "Early research ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ability ... optogenetics — is key to exciting advances in the study and mapping of ... projected via free-space optics stimulates small, transparent organisms and excites neurons within superficial ...
(Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
Breaking Biology Technology:
(Date:11/30/2016)... , Nov. 30, 2016  higi SH llc ... partnership initiative targeting national brands, industry thought-leaders and ... their respective audiences for taking steps to live ... inception in 2012, higi has built the largest ... over 38 million people who have conducted over ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today ... athletes and their trainers non-invasively measure hemoglobin, ... Pulse Rate, and Respiration Rate in approximately 30 seconds. ... users easy and immediate access to key data about ... of a training regimen. Hemoglobin carries ...
(Date:11/17/2016)... Nov. 17, 2016 Global Market Watch: ... (Disease-Based Banks, Population-Based Banks and Academics) market is to witness ... Private Biobanks shows the highest Compounded Annual Growth Rate (CAGR) ... region during the analysis period 2014-2020. North America ... 9.95% followed by Europe at 9.56% ...
Breaking Biology News(10 mins):